Teva and Amgen resolve ongoing dispute over generic cinacalcet

Israeli generics giant Teva Pharmaceutical Industries (NYSE: TEVA) announced that it has resolved its ongoing dispute with Amgen (Nasdaq: AMGN) over Teva’s generic cinacalcet HCl, marketed by the US biotech major as Sensipar and Mimpara product.

Teva and Amgen have been involved in patent infringement litigation, and Teva recently received approval for, and launched its generic product in the USA.

By virtue of the settlement, the litigation between the parties will be ended and Teva has agreed to stop selling its generic product until its license date in mid-year 2021, or earlier under certain circumstances. Teva will pay Amgen an undisclosed amount as part of the settlement. That amount and other terms of the settlement remain confidential.